Soft tissue sarcomas are a group of malignant tumors that can affect children and adults and grow in the soft tissues of the body. It is a relatively rare malignancy, affecting only 2-3 people per 100,000 people each year. Soft tissue sarcomas can grow in muscle, deep layers of skin, fat, blood vessels, nerves, and other connective tissues. Although they can appear anywhere in the body, most begin in the arms and legs.
The global Extremities Soft Tissue Sarcomas market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the 鈥淓xtremities Soft Tissue Sarcomas Industry Forecast鈥� looks at past sales and reviews total world Extremities Soft Tissue Sarcomas sales in 2023, providing a comprehensive analysis by region and market sector of projected Extremities Soft Tissue Sarcomas sales for 2024 through 2030. With Extremities Soft Tissue Sarcomas sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Extremities Soft Tissue Sarcomas industry.
This Insight Report provides a comprehensive analysis of the global Extremities Soft Tissue Sarcomas landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Extremities Soft Tissue Sarcomas portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Extremities Soft Tissue Sarcomas market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Extremities Soft Tissue Sarcomas and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Extremities Soft Tissue Sarcomas.
United States market for Extremities Soft Tissue Sarcomas is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Extremities Soft Tissue Sarcomas is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Extremities Soft Tissue Sarcomas is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Extremities Soft Tissue Sarcomas players cover Novartis, Pfizer, Bristol-Myers Squibb, Merck, GSK, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Extremities Soft Tissue Sarcomas market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Chemotherapy Drugs
Targeted therapy Drugs
Immunotherapy Drugs
Hormonal therapy Drugs
Segmentation by Application:
Hospital
Clinic
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Novartis
Pfizer
Bristol-Myers Squibb
Merck
GSK
Bayer
Advenchen Laboratories
Blueprint Medicines
BioHorizons
Biomet
Geistlich
Smith & Nephew
RTI Biologics
MiMedx
LifeCell
Atrium Medical
Zimmer Holdings
Cook Medical
Dentsply
Medtronic
Stryker
Ethicon
Boston Scientific
American Medical Systems
Integra LifeSciences and Citagenix
Key Questions Addressed in this Report
What is the 10-year outlook for the global Extremities Soft Tissue Sarcomas market?
What factors are driving Extremities Soft Tissue Sarcomas market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Extremities Soft Tissue Sarcomas market opportunities vary by end market size?
How does Extremities Soft Tissue Sarcomas break out by Type, by Application?
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Extremities Soft Tissue Sarcomas Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Extremities Soft Tissue Sarcomas by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Extremities Soft Tissue Sarcomas by Country/Region, 2019, 2023 & 2030
2.2 Extremities Soft Tissue Sarcomas Segment by Type
2.2.1 Chemotherapy Drugs
2.2.2 Targeted therapy Drugs
2.2.3 Immunotherapy Drugs
2.2.4 Hormonal therapy Drugs
2.3 Extremities Soft Tissue Sarcomas Sales by Type
2.3.1 Global Extremities Soft Tissue Sarcomas Sales 麻豆原创 Share by Type (2019-2024)
2.3.2 Global Extremities Soft Tissue Sarcomas Revenue and 麻豆原创 Share by Type (2019-2024)
2.3.3 Global Extremities Soft Tissue Sarcomas Sale Price by Type (2019-2024)
2.4 Extremities Soft Tissue Sarcomas Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Extremities Soft Tissue Sarcomas Sales by Application
2.5.1 Global Extremities Soft Tissue Sarcomas Sale 麻豆原创 Share by Application (2019-2024)
2.5.2 Global Extremities Soft Tissue Sarcomas Revenue and 麻豆原创 Share by Application (2019-2024)
2.5.3 Global Extremities Soft Tissue Sarcomas Sale Price by Application (2019-2024)
3 Global by Company
3.1 Global Extremities Soft Tissue Sarcomas Breakdown Data by Company
3.1.1 Global Extremities Soft Tissue Sarcomas Annual Sales by Company (2019-2024)
3.1.2 Global Extremities Soft Tissue Sarcomas Sales 麻豆原创 Share by Company (2019-2024)
3.2 Global Extremities Soft Tissue Sarcomas Annual Revenue by Company (2019-2024)
3.2.1 Global Extremities Soft Tissue Sarcomas Revenue by Company (2019-2024)
3.2.2 Global Extremities Soft Tissue Sarcomas Revenue 麻豆原创 Share by Company (2019-2024)
3.3 Global Extremities Soft Tissue Sarcomas Sale Price by Company
3.4 Key Manufacturers Extremities Soft Tissue Sarcomas Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Extremities Soft Tissue Sarcomas Product Location Distribution
3.4.2 Players Extremities Soft Tissue Sarcomas Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Extremities Soft Tissue Sarcomas by Geographic Region
4.1 World Historic Extremities Soft Tissue Sarcomas 麻豆原创 Size by Geographic Region (2019-2024)
4.1.1 Global Extremities Soft Tissue Sarcomas Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Extremities Soft Tissue Sarcomas Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Extremities Soft Tissue Sarcomas 麻豆原创 Size by Country/Region (2019-2024)
4.2.1 Global Extremities Soft Tissue Sarcomas Annual Sales by Country/Region (2019-2024)
4.2.2 Global Extremities Soft Tissue Sarcomas Annual Revenue by Country/Region (2019-2024)
4.3 Americas Extremities Soft Tissue Sarcomas Sales Growth
4.4 APAC Extremities Soft Tissue Sarcomas Sales Growth
4.5 Europe Extremities Soft Tissue Sarcomas Sales Growth
4.6 Middle East & Africa Extremities Soft Tissue Sarcomas Sales Growth
5 Americas
5.1 Americas Extremities Soft Tissue Sarcomas Sales by Country
5.1.1 Americas Extremities Soft Tissue Sarcomas Sales by Country (2019-2024)
5.1.2 Americas Extremities Soft Tissue Sarcomas Revenue by Country (2019-2024)
5.2 Americas Extremities Soft Tissue Sarcomas Sales by Type (2019-2024)
5.3 Americas Extremities Soft Tissue Sarcomas Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Extremities Soft Tissue Sarcomas Sales by Region
6.1.1 APAC Extremities Soft Tissue Sarcomas Sales by Region (2019-2024)
6.1.2 APAC Extremities Soft Tissue Sarcomas Revenue by Region (2019-2024)
6.2 APAC Extremities Soft Tissue Sarcomas Sales by Type (2019-2024)
6.3 APAC Extremities Soft Tissue Sarcomas Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Extremities Soft Tissue Sarcomas by Country
7.1.1 Europe Extremities Soft Tissue Sarcomas Sales by Country (2019-2024)
7.1.2 Europe Extremities Soft Tissue Sarcomas Revenue by Country (2019-2024)
7.2 Europe Extremities Soft Tissue Sarcomas Sales by Type (2019-2024)
7.3 Europe Extremities Soft Tissue Sarcomas Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Extremities Soft Tissue Sarcomas by Country
8.1.1 Middle East & Africa Extremities Soft Tissue Sarcomas Sales by Country (2019-2024)
8.1.2 Middle East & Africa Extremities Soft Tissue Sarcomas Revenue by Country (2019-2024)
8.2 Middle East & Africa Extremities Soft Tissue Sarcomas Sales by Type (2019-2024)
8.3 Middle East & Africa Extremities Soft Tissue Sarcomas Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Extremities Soft Tissue Sarcomas
10.3 Manufacturing Process Analysis of Extremities Soft Tissue Sarcomas
10.4 Industry Chain Structure of Extremities Soft Tissue Sarcomas
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Extremities Soft Tissue Sarcomas Distributors
11.3 Extremities Soft Tissue Sarcomas Customer
12 World Forecast Review for Extremities Soft Tissue Sarcomas by Geographic Region
12.1 Global Extremities Soft Tissue Sarcomas 麻豆原创 Size Forecast by Region
12.1.1 Global Extremities Soft Tissue Sarcomas Forecast by Region (2025-2030)
12.1.2 Global Extremities Soft Tissue Sarcomas Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Extremities Soft Tissue Sarcomas Forecast by Type (2025-2030)
12.7 Global Extremities Soft Tissue Sarcomas Forecast by Application (2025-2030)
13 Key Players Analysis
13.1 Novartis
13.1.1 Novartis Company Information
13.1.2 Novartis Extremities Soft Tissue Sarcomas Product Portfolios and Specifications
13.1.3 Novartis Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Novartis Main Business Overview
13.1.5 Novartis Latest Developments
13.2 Pfizer
13.2.1 Pfizer Company Information
13.2.2 Pfizer Extremities Soft Tissue Sarcomas Product Portfolios and Specifications
13.2.3 Pfizer Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Pfizer Main Business Overview
13.2.5 Pfizer Latest Developments
13.3 Bristol-Myers Squibb
13.3.1 Bristol-Myers Squibb Company Information
13.3.2 Bristol-Myers Squibb Extremities Soft Tissue Sarcomas Product Portfolios and Specifications
13.3.3 Bristol-Myers Squibb Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Bristol-Myers Squibb Main Business Overview
13.3.5 Bristol-Myers Squibb Latest Developments
13.4 Merck
13.4.1 Merck Company Information
13.4.2 Merck Extremities Soft Tissue Sarcomas Product Portfolios and Specifications
13.4.3 Merck Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Merck Main Business Overview
13.4.5 Merck Latest Developments
13.5 GSK
13.5.1 GSK Company Information
13.5.2 GSK Extremities Soft Tissue Sarcomas Product Portfolios and Specifications
13.5.3 GSK Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 GSK Main Business Overview
13.5.5 GSK Latest Developments
13.6 Bayer
13.6.1 Bayer Company Information
13.6.2 Bayer Extremities Soft Tissue Sarcomas Product Portfolios and Specifications
13.6.3 Bayer Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Bayer Main Business Overview
13.6.5 Bayer Latest Developments
13.7 Advenchen Laboratories
13.7.1 Advenchen Laboratories Company Information
13.7.2 Advenchen Laboratories Extremities Soft Tissue Sarcomas Product Portfolios and Specifications
13.7.3 Advenchen Laboratories Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Advenchen Laboratories Main Business Overview
13.7.5 Advenchen Laboratories Latest Developments
13.8 Blueprint Medicines
13.8.1 Blueprint Medicines Company Information
13.8.2 Blueprint Medicines Extremities Soft Tissue Sarcomas Product Portfolios and Specifications
13.8.3 Blueprint Medicines Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Blueprint Medicines Main Business Overview
13.8.5 Blueprint Medicines Latest Developments
13.9 BioHorizons
13.9.1 BioHorizons Company Information
13.9.2 BioHorizons Extremities Soft Tissue Sarcomas Product Portfolios and Specifications
13.9.3 BioHorizons Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 BioHorizons Main Business Overview
13.9.5 BioHorizons Latest Developments
13.10 Biomet
13.10.1 Biomet Company Information
13.10.2 Biomet Extremities Soft Tissue Sarcomas Product Portfolios and Specifications
13.10.3 Biomet Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Biomet Main Business Overview
13.10.5 Biomet Latest Developments
13.11 Geistlich
13.11.1 Geistlich Company Information
13.11.2 Geistlich Extremities Soft Tissue Sarcomas Product Portfolios and Specifications
13.11.3 Geistlich Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Geistlich Main Business Overview
13.11.5 Geistlich Latest Developments
13.12 Smith & Nephew
13.12.1 Smith & Nephew Company Information
13.12.2 Smith & Nephew Extremities Soft Tissue Sarcomas Product Portfolios and Specifications
13.12.3 Smith & Nephew Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Smith & Nephew Main Business Overview
13.12.5 Smith & Nephew Latest Developments
13.13 RTI Biologics
13.13.1 RTI Biologics Company Information
13.13.2 RTI Biologics Extremities Soft Tissue Sarcomas Product Portfolios and Specifications
13.13.3 RTI Biologics Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 RTI Biologics Main Business Overview
13.13.5 RTI Biologics Latest Developments
13.14 MiMedx
13.14.1 MiMedx Company Information
13.14.2 MiMedx Extremities Soft Tissue Sarcomas Product Portfolios and Specifications
13.14.3 MiMedx Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 MiMedx Main Business Overview
13.14.5 MiMedx Latest Developments
13.15 LifeCell
13.15.1 LifeCell Company Information
13.15.2 LifeCell Extremities Soft Tissue Sarcomas Product Portfolios and Specifications
13.15.3 LifeCell Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 LifeCell Main Business Overview
13.15.5 LifeCell Latest Developments
13.16 Atrium Medical
13.16.1 Atrium Medical Company Information
13.16.2 Atrium Medical Extremities Soft Tissue Sarcomas Product Portfolios and Specifications
13.16.3 Atrium Medical Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024)
13.16.4 Atrium Medical Main Business Overview
13.16.5 Atrium Medical Latest Developments
13.17 Zimmer Holdings
13.17.1 Zimmer Holdings Company Information
13.17.2 Zimmer Holdings Extremities Soft Tissue Sarcomas Product Portfolios and Specifications
13.17.3 Zimmer Holdings Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024)
13.17.4 Zimmer Holdings Main Business Overview
13.17.5 Zimmer Holdings Latest Developments
13.18 Cook Medical
13.18.1 Cook Medical Company Information
13.18.2 Cook Medical Extremities Soft Tissue Sarcomas Product Portfolios and Specifications
13.18.3 Cook Medical Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024)
13.18.4 Cook Medical Main Business Overview
13.18.5 Cook Medical Latest Developments
13.19 Dentsply
13.19.1 Dentsply Company Information
13.19.2 Dentsply Extremities Soft Tissue Sarcomas Product Portfolios and Specifications
13.19.3 Dentsply Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024)
13.19.4 Dentsply Main Business Overview
13.19.5 Dentsply Latest Developments
13.20 Medtronic
13.20.1 Medtronic Company Information
13.20.2 Medtronic Extremities Soft Tissue Sarcomas Product Portfolios and Specifications
13.20.3 Medtronic Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024)
13.20.4 Medtronic Main Business Overview
13.20.5 Medtronic Latest Developments
13.21 Stryker
13.21.1 Stryker Company Information
13.21.2 Stryker Extremities Soft Tissue Sarcomas Product Portfolios and Specifications
13.21.3 Stryker Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024)
13.21.4 Stryker Main Business Overview
13.21.5 Stryker Latest Developments
13.22 Ethicon
13.22.1 Ethicon Company Information
13.22.2 Ethicon Extremities Soft Tissue Sarcomas Product Portfolios and Specifications
13.22.3 Ethicon Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024)
13.22.4 Ethicon Main Business Overview
13.22.5 Ethicon Latest Developments
13.23 Boston Scientific
13.23.1 Boston Scientific Company Information
13.23.2 Boston Scientific Extremities Soft Tissue Sarcomas Product Portfolios and Specifications
13.23.3 Boston Scientific Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024)
13.23.4 Boston Scientific Main Business Overview
13.23.5 Boston Scientific Latest Developments
13.24 American Medical Systems
13.24.1 American Medical Systems Company Information
13.24.2 American Medical Systems Extremities Soft Tissue Sarcomas Product Portfolios and Specifications
13.24.3 American Medical Systems Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024)
13.24.4 American Medical Systems Main Business Overview
13.24.5 American Medical Systems Latest Developments
13.25 Integra LifeSciences and Citagenix
13.25.1 Integra LifeSciences and Citagenix Company Information
13.25.2 Integra LifeSciences and Citagenix Extremities Soft Tissue Sarcomas Product Portfolios and Specifications
13.25.3 Integra LifeSciences and Citagenix Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024)
13.25.4 Integra LifeSciences and Citagenix Main Business Overview
13.25.5 Integra LifeSciences and Citagenix Latest Developments
14 Research Findings and Conclusion
听
听
*If Applicable.
